Tier 4 — mechanistic

Effect of Vitamin C and Its Derivatives on Collagen Synthesis and Cross-Linking by Normal Human Fibroblasts

N. Boyera, I. Galey, B.A. Bernard
International Journal of Cosmetic Science 1998 20(3):151-158

Bibliography

PubMed
PMID 18505499
DOI
10.1046/j.1467-2494.1998.171747.x
Funding
Not stated as a separate funding statement. All three authors are employees of the Life Sciences Department, L'Oréal Advanced Research Laboratories (Clichy-Cédex, France), which funded and conducted the study in-house. Biohack Blueprint assessment: this is an industry (L'Oréal) in-house mechanistic study evaluating vitamin C and two proprietary-adjacent vitamin C derivatives with cosmetic anti-ageing applications. No independent or academic funding source is involved.
Competing interests
Not stated as a formal declaration (the article predates modern COI disclosure norms). All three authors are L'Oréal employees; the compounds tested are relevant to L'Oréal's cosmetic anti-ageing formulations.

Study snapshot

DesignIn vitro mechanistic study: (1) indirect immunofluorescence of type I collagen deposits by normal human fibroblasts (NHF) in monolayer culture; (2) three-dimensional collagen lattice contraction model
ModelNormal human dermal fibroblasts (NHF) isolated from plastic surgery skin specimens, two donor sources, passage 6-12
SampleNot applicable — in vitro study; triplicate culture dishes or lattices per condition, repeated across two independent experiments per model
InterventionVitamin C (sodium ascorbate), vitamin C-phosphate, or vitamin C-glucoside applied directly to fibroblast cultures at 10⁻³, 10⁻⁴ and 10⁻⁵ M concentrations — not an oral or dietary intervention
Duration96 hours for the monolayer collagen-deposit assay; up to 30 days for the lattice-contraction assay
EndpointsType I collagen deposits by immunofluorescence; Three-dimensional collagen lattice contraction (diameter over time); Cytotoxicity (neutral red incorporation)

What the study showed, in plain terms

Vitamin C is a required cofactor for two enzymes — lysyl and prolyl hydroxylase — that the body needs to build a stable, cross-linked collagen network. Without enough vitamin C, this process fails; that's the underlying biology of scurvy. This laboratory study looked at how vitamin C, and two more stable vitamin C derivatives, affect collagen production and cross-linking directly in skin cells grown in a dish.

All three forms increased collagen deposits and strengthened collagen network contraction in a dose-dependent way, with no toxicity at the concentrations tested. This is the kind of mechanistic study often cited to justify pairing vitamin C with a collagen supplement.

It is important to be precise about what this paper does and doesn't show. It is an in vitro fibroblast study funded and authored entirely by a cosmetics manufacturer (L'Oréal) — it did not test oral collagen peptide supplementation, did not involve any human participants, and cannot on its own support a claim that adding vitamin C to an oral collagen peptide product improves outcomes in people.

Key findings

  • Vitamin C, vitamin C-phosphate and vitamin C-glucoside all produced a dose-dependent increase in type I collagen deposits by fibroblasts, most pronounced at 10⁻³ M.
  • All three compounds enhanced contraction of the three-dimensional collagen lattice, indicating stronger cross-linked matrix reorganisation, with vitamin C-glucoside the most potent in this specific assay.
  • No cytotoxicity was observed at 10⁻³, 10⁻⁴ or 10⁻⁵ M for any of the three compounds (some cytotoxicity was seen only at a much higher, non-physiological 10⁻² M concentration).
  • The two more chemically stable vitamin C derivatives (vitamin C-phosphate, vitamin C-glucoside) showed comparable biological activity to standard vitamin C, but with different relative potency between the two assay models.

What this study can and cannot tell us

  • Purely in vitro — no human data, no oral or dietary route of administration, and no test of hydrolysed collagen peptides at all.
  • Cannot establish oral bioavailability, appropriate human dosing, or any clinical outcome; direct-to-cell concentrations used here have no established equivalence to an oral supplement dose.
  • Funded and authored entirely by a cosmetics manufacturer with a direct commercial interest in the tested vitamin C derivatives.
  • Should not be cited on its own as evidence that combining vitamin C with an oral hydrolysed collagen peptide supplement improves skin outcomes in humans — a bridging human RCT would be required to support that specific claim.

Related papers in the corpus

Tier 2
Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men: a randomised controlled trial
Denise Zdzieblik et al. · British Journal of Nutrition · 2015
Tier 3
Vitamin C–Enriched Gelatin Supplementation before Intermittent Activity Augments Collagen Synthesis
Gregory Shaw et al. · American Journal of Clinical Nutrition · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology